Hematology

A final analysis of the pivotal HOPE-B study was presented at ASGCT 2022.

The clinical professor of pediatrics at Stanford Medicine discussed positive interim findings from a phase 1 study of RP-L301.

Review top news and interview highlights from the week ending May 20, 2022.

Findings from a preclinical study, which are in contrast with the current biphasic recovery model, have implications for both HSC transplantation and gene therapy.

The assistant professor of oncology at UNC School of Medicine discussed the first-in-human study being conducted with CT-0508.

Investigators from Seattle Children’s Hospital found that engineered T-cell regulatory products demonstrated significant suppression of effector T cells.

The trial met its primary efficacy end point, and participants reported improvements in quality-of-life factors such as outlook on the future and feelings about having hemophilia.

Catch up on the latest news and announcements in cell and gene therapies presented at the annual ASGCT meeting.

In a late-breaking presentation at ASGCT 2022, investigators shared preclinical results of a gene-editing strategy that seeks to reactivate developmentally silenced fetal hemoglobin (HbF, α2γ2) in order to replace defective sickle hemoglobin (HbS, α2βS2).

Further data from Mustang Bio’s phase 1/2 trial will be presented at the EHA 2022 Congress.

Review top news and interview highlights from the week ending May 13, 2022.

The investigational therapy is also currently being evaluated in a clinical trial for sickle cell disease.

Caribou will present the initial data at the upcoming European Hematology Association (EHA) meeting in June.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The cell therapy is the first to come out of the company’s proprietary ARC-SparX platform.

Tim Lu, MD, PhD, CEO and co-founder of gene circuit company Senti Bio, joins CGTL to discuss his company's approach to creating "smarter" therapies, including its CAR-NK platform.

Marker Therapeutics is taking a multi-antigen approach to developing next-generation T-cell therapies.

Review top news and interview highlights from the week ending May 6, 2022.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Although the agency has cleared the trial to restart, Pfizer will extend the voluntary hold on dosing new patients while the company talks through conditions of the restart.

Enrollment is ongoing in the phase 1 CEDAR trial, which plans to dose the first patient later in 2022.

There was a continued trend toward improvement of overall survival with omidubicel at 73% compared with UCBT at 60%.

Rami Elghandour, chairman and CEO of Arcellx, shares updates on the phase 1 trial of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma.

Review top news and interview highlights from the week ending April 29, 2022.

The real-world analysis addresses a clear gap in data from previous and ongoing cell therapy clinical trials.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The analysis of data from ZUMA-7 demonstrated significant efficacy for axi-cel over second-line standard treatment.

The gene-edited CAR T-cell therapy is currently being investigated in a phase 2 clinical trial.

Tisa-cel was associated with a more favorable safety profile in the analysis.

In this population, median progression-free survival was nearly 40 months.